Under construction – not a live service
Sign in
Taking people in GermanyNo phase

Diagnostic Criteria in Cardiac Sarcoidosis

Key facts

Where
Leipzig, GermanySee the site

Where in Germany

  • Heart Center of LeipzigLeipzig, GermanyContact: Borislav Dinov, PhDTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Heart Center Leipzig - University Hospital
Trial code
NCT04737317
Record updated
9 May 2023
Original description
The purpose of the study is to evaluate the accuracy of the current diagnostic criteria of cardiac sarcoidosis.Read full original descriptionShow less

Evaluation of Diagnostic Criteria in Cardiac Sarcoidosis - an Observational Study

The purpose of the study is to evaluate the accuracy of the current diagnostic criteria of cardiac sarcoidosis.

Inclusion: patients with suspected CS due to the following presentations:; age < 65 years and new higher degree AV block, causative coronary artery disease excluded; age < 65 years and new ventricular tachycardia, causative coronary artery disease excluded; age < 65 years and ventricular tachycardia, causative coronary artery disease excluded; extracardiac sarcoidosis and cardiac involvement suggested (palpitations, abnormal ECG, abnormal echocardiography); To diagnose CS one of the following diagnostic tools will be used:; World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG); Heart Rhythm Society expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis; Japanese Society of Nuclear Cardiology (JSNC); Patients whit histological confirmation from myocardial tissue fullfil will be defined as proven CS. (Group 1); Patients with clinical and imaging findings highly suggesting CS, but without histological confirmation from myocardial biopsy will be defined as probable CS (Group 2); Patients who do not fullfil the criteria or exhibiting findings suggesting an alternative, more likely diagnosis, will be considered as unlikely CS (Group 3).

Exclusion: noncompliant patients refusing the recommended therapy; age < 18 years; unable or unwilling to provide informed consent; patients who are pregnant or lactating.

ClinicalTrials.gov NCT04737317